x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Israel | Not applicable | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. employer identification no.) | |
3 Hatnufa Street, Floor 6, Yokneam Ilit, Israel | 2069203 | |
(Address of principal executive offices) | (Zip Code) |
Large accelerated filer o | Accelerated filer o |
Non-accelerated filer o | Smaller reporting company x |
(Do not check if a smaller reporting company) | Emerging growth company x |
Page No. | ||
September 30, | December 31, | ||||||
2017 | 2016 | ||||||
ASSETS | |||||||
CURRENT ASSETS | |||||||
Cash and cash equivalents | $ | 12,928 | $ | 23,678 | |||
Trade receivable, net | 1,265 | 1,254 | |||||
Prepaid expenses and other current assets | 1,703 | 1,291 | |||||
Inventory | 3,500 | 3,264 | |||||
Total current assets | 19,396 | 29,487 | |||||
LONG-TERM ASSETS | |||||||
Other long term assets | 1,182 | 1,018 | |||||
Property and equipment, net | 906 | 1,258 | |||||
Total long-term assets | 2,088 | 2,276 | |||||
Total assets | $ | 21,484 | $ | 31,763 |
September 30, | December 31, | ||||||
2017 | 2016 | ||||||
LIABILITIES AND SHAREHOLDERS’ EQUITY | |||||||
CURRENT LIABILITIES | |||||||
Current maturities of long term loan | $ | 5,663 | $ | 7,495 | |||
Trade payables | 2,426 | 3,424 | |||||
Employees and payroll accruals | 858 | 1,019 | |||||
Deferred revenues and customers advances | 133 | 54 | |||||
Other current liabilities | 537 | 406 | |||||
Total current liabilities | 9,617 | 12,398 | |||||
LONG-TERM LIABILITIES | |||||||
Long term loan, net of current maturities | 10,003 | 10,518 | |||||
Deferred revenues | 250 | 284 | |||||
Other long-term liabilities | 274 | 303 | |||||
Total long-term liabilities | 10,527 | 11,105 | |||||
Total liabilities | 20,144 | 23,503 | |||||
COMMITMENTS AND CONTINGENT LIABILITIES | |||||||
Shareholders’ equity: | |||||||
Share capital | |||||||
Ordinary shares, par value NIS 0.01 per share-Authorized: 250,000,000 shares at September 30, 2017 and December 31, 2016; Issued and outstanding: 21,823,771 and 16,338,257 shares at September 30, 2017 and December 31, 2016, respectively | 60 | 45 | |||||
Additional paid-in capital | 126,338 | 114,707 | |||||
Accumulated deficit | (125,058 | ) | (106,492 | ) | |||
Total shareholders’ equity | 1,340 | 8,260 | |||||
Total liabilities and shareholders’ equity | $ | 21,484 | $ | 31,763 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2017 | 2016 | 2017 | 2016 | ||||||||||||
Revenues | $ | 1,732 | $ | 1,400 | $ | 6,238 | $ | 4,278 | |||||||
Cost of revenues | 1,024 | 1,110 | 3,740 | 3,410 | |||||||||||
Gross profit | 708 | 290 | 2,498 | 868 | |||||||||||
Operating expenses: | |||||||||||||||
Research and development, net | 1,618 | 1,968 | 4,433 | 6,737 | |||||||||||
Sales and marketing | 2,637 | 3,774 | 8,643 | 10,577 | |||||||||||
General and administrative | 1,805 | 1,951 | 5,796 | 5,960 | |||||||||||
Total operating expenses | 6,060 | 7,693 | 18,872 | 23,274 | |||||||||||
Operating loss | (5,352 | ) | (7,403 | ) | (16,374 | ) | (22,406 | ) | |||||||
Loss on extinguishment of debt | — | — | 313 | — | |||||||||||
Financial expenses, net | 479 | 508 | 1,843 | 1,514 | |||||||||||
Loss before income taxes | (5,831 | ) | (7,911 | ) | (18,530 | ) | (23,920 | ) | |||||||
Income taxes | 15 | 9 | 25 | 39 | |||||||||||
Net loss | $ | (5,846 | ) | $ | (7,920 | ) | $ | (18,555 | ) | $ | (23,959 | ) | |||
Net loss per ordinary share, basic and diluted | $ | (0.27 | ) | $ | (0.62 | ) | $ | (1.00 | ) | $ | (1.92 | ) | |||
Weighted average number of shares used in computing net loss per ordinary share, basic and diluted | 21,660,757 | 12,759,887 | 18,463,444 | 12,495,433 |
Ordinary Share | Additional paid-in capital | Accumulated deficit | Total shareholders’ equity | |||||||||||
Number | Amount | |||||||||||||
Balance as of January 1, 2016 | 12,222,583 | 33 | 94,876 | (73,989 | ) | 20,920 | ||||||||
Share-based compensation to employees and non-employees | — | — | 3,398 | — | 3,398 | |||||||||
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees | 128,496 | 1 | 17 | — | 18 | |||||||||
Issuance of ordinary shares in at-the-market offering, net of issuance expenses in the amount of $468 | 692,062 | 2 | 4,097 | — | 4,099 | |||||||||
Issuance of warrants to purchase ordinary shares | — | — | 1,239 | — | 1,239 | |||||||||
Cashless exercise of warrants into ordinary shares | 45,116 | *) | *) | — | — | |||||||||
Issuance of ordinary shares and warrants to purchase ordinary shares in follow-on public offering, net of issuance expenses in an amount of $1,099 | 3,250,000 | 9 | 11,080 | — | 11,089 | |||||||||
Net loss | — | — | — | (32,503 | ) | (32,503 | ) | |||||||
Balance as of December 31, 2016 | 16,338,257 | 45 | 114,707 | (106,492 | ) | 8,260 | ||||||||
Cumulative effect to stock based compensation from adoption of a new accounting standard | — | — | 11 | (11 | ) | — | ||||||||
Share-based compensation to employees and non-employees | — | — | 2,597 | — | 2,597 | |||||||||
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees (1) | 105,606 | *) | 28 | — | 28 | |||||||||
Issuance of ordinary shares in at-the-market offering, net of issuance expenses in the amount of $439 (2) | 5,379,908 | 15 | 8,995 | — | 9,010 | |||||||||
Net loss | — | — | — | (18,555 | ) | (18,555 | ) | |||||||
Balance as of September 30, 2017 | 21,823,771 | 60 | 126,338 | (125,058 | ) | 1,340 |
*) | Represents an amount lower than $1. |
(1) | See Note 8b to the condensed consolidated financial statements |
(2) | See Note 8e to the condensed consolidated financial statements |
Nine Months Ended September 30, | |||||||
2017 | 2016 | ||||||
Cash flows from operating activities: | |||||||
Net loss | $ | (18,555 | ) | $ | (23,959 | ) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
Depreciation | 516 | 503 | |||||
Share-based compensation to employees and non- employees | 2,597 | 2,458 | |||||
Deferred taxes | (20 | ) | (64 | ) | |||
Loss on extinguishment of debt | 313 | — | |||||
Financial expenses related to long term loan | 87 | 495 | |||||
Changes in assets and liabilities: | |||||||
Trade receivables, net | (11 | ) | 1,202 | ||||
Prepaid expenses and other current and long term assets | (556 | ) | (804 | ) | |||
Inventories | (381 | ) | (1,004 | ) | |||
Trade payables | (1,048 | ) | 960 | ||||
Employees and payroll accruals | (161 | ) | (285 | ) | |||
Deferred revenues and advances from customers | 45 | 116 | |||||
Other current and long term liabilities | 102 | 182 | |||||
Net cash used in operating activities | (17,072 | ) | (20,200 | ) | |||
Cash flows from investing activities: | |||||||
Purchase of property and equipment | (19 | ) | (408 | ) | |||
Net cash used in investing activities | (19 | ) | (408 | ) | |||
Cash flows from financing activities: | |||||||
Issuance of ordinary shares upon exercise of options to purchase ordinary shares by employees and non-employees | 28 | 23 | |||||
Proceeds from long term loan | — | 12,000 | |||||
Debt issuance cost | — | (441 | ) | ||||
Repayment of long term loan | (2,747 | ) | (554 | ) | |||
Issuance of ordinary shares in at-the-market offering, net of issuance expenses paid in the amount of $389 (1) | 9,060 | 4,110 | |||||
Net cash provided by financing activities | 6,341 | 15,138 | |||||
Decrease in cash and cash equivalents | (10,750 | ) | (5,470 | ) | |||
Cash and cash equivalents at beginning of period | 23,678 | 17,869 | |||||
Cash and cash equivalents at end of period | $ | 12,928 | $ | 12,399 | |||
Supplemental disclosures of non-cash flow information | |||||||
At-the-market offering expenses not yet paid | $ | 50 | $ | 11 | |||
Classification of inventory to property and equipment, net | $ | 145 | $ | 113 |
a. | ReWalk Robotics Ltd. (“RRL”, and together with its subsidiaries, the “Company”) was incorporated under the laws of the State of Israel on June 20, 2001 and commenced operations on the same date. |
b. | RRL has two wholly-owned subsidiaries: (i) ReWalk Robotics Inc., incorporated under the laws of Delaware on February 15, 2012; and (ii) ReWalk Robotics GMBH. incorporated under the laws of Germany on January 14, 2013. |
c. | During the nine months ended September 30, 2017, the Company issued and sold 5,379,908 ordinary shares at an average price of $1.76 per share under its ATM Offering Program (as defined in Note 8e). The gross proceeds to the Company were $9.4 million, and the net aggregate proceeds after deducting commissions, fees and offering expenses in the amount of $439 thousand were $9.0 million. As a result, from the inception of the ATM Offering Program in May 2016 until September 30, 2017, the Company has issued and sold 6,071,970 ordinary shares at an average price of $2.31 per share under its ATM Offering Program, with gross proceeds of $14.0 million, and net aggregate proceeds of $13.1 million after deducting commissions, fees and offering expenses in the amount of $907 thousand. The Company may raise up to $25 million under its ATM Offering Program pursuant to the terms of its agreement with the sales agent. However, due to limitations under the rules of Form S-3, which have applied to the Company since it filed its annual report on Form 10-K for the fiscal year ended December 31, 2016 on February 17, 2017, taking into account ordinary shares issued and settled under the Company’s ATM Offering Program since February 17, 2017, as of September 30, 2017, the Company may issue up to $4.3 million in primary offerings under its effective shelf registration statement on Form S-3 (File No. 333- 209833) (the “Form S-3”), including its ATM Offering Program, during the 12 months following February 17, 2017, unless and until it is no longer subject to such limitations. See Note 8e for more information about the Company’s ATM Offering Program and the related limitations under its Form S-3. |
d. | The Company depends on one contract manufacturer. Reliance on this vendor makes the Company vulnerable to possible capacity constraints and reduced control over component availability, delivery schedules, manufacturing yields and costs. This vendor accounted for 0% and 12% of the Company's total trade payables as of September 30, 2017 and December 31, 2016, respectively. |
e. | On January 9, 2017, the Company announced its plan to reduce total operating expenses in 2017 by up to 30% as compared to 2016. The Company has been working toward such reductions through a combination of targeted savings, including by establishing quality improvement initiatives and lowering overall product cost, realigning the Company’s staffing priorities and reducing the size of its staff, including its reimbursement personnel, reducing spending on external appeals, and lowering other corporate spending. |
f. | The Company had an accumulated deficit in the total amount of $125.1 million as of September 30, 2017 and further losses are anticipated in the development of its business. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. |
a. | The significant accounting policies applied in the audited consolidated financial statements of the Company as disclosed in the Company's annual report on Form 10-K for the year ended December 31, 2016 filed with the SEC on February 17, 2017, as amended on Form 10-K/A filed with the SEC on April 27, 2017 (the “2016 Form 10-K”), are applied consistently in these unaudited interim condensed consolidated financial statements. |
b. | Recent Accounting Pronouncements: |
c. | Concentrations of Credit Risks: |
d. | Warranty provision |
US Dollars in thousands | |||
Balance at December 31, 2016 | $ | 498 | |
Provision | 311 | ||
Usage | (275 | ) | |
Balance at September 30, 2017 | $ | 534 |
September 30, | December 31, | ||||||
2017 | 2016 | ||||||
Finished products | 3,500 | 3,264 | |||||
$ | 3,500 | $ | 3,264 |
a. | Purchase commitments: |
b. | Royalties: |
c. | Liens: |
d. | Legal Claims: |
• | Dismissed Actions: |
◦ | On September 20, November 3, November 9, and November 10, 2016, respectively, four putative class actions on behalf of alleged shareholders that purchased or acquired the Company's ordinary shares pursuant and/or traceable to the registration statement used in connection with the Company's IPO were commenced in the Superior Court of the State of California, County of San Mateo. The actions were filed against the Company, certain of the Company's current and former directors and officers, and the underwriters of the Company's IPO. We refer to these actions as the “California State Court Actions.” The complaints in the California State Court Actions asserted various claims under the Securities Act. Each of the California State Court Actions was dismissed for lack of personal jurisdiction in January 2017. |
◦ | On January 24, 2017, a substantially similar class action was commenced in the United States District Court for the Northern District of California (Case No. 4:17-cv-362) against the same defendants as in the California State Court Actions plus certain additional defendants. This action is referred to as the “California Federal Court Action.” On March 23, 2017, this case was voluntarily dismissed. |
• | Pending Actions: |
◦ | On or about October 31, 2016, a class action with claims substantially similar to the California State Court Actions was commenced in the Massachusetts Superior Court, Suffolk County, by a different plaintiff (Civ. Action No. 16-3336), alleging claims under Section 11 of the Securities Act against the Company, certain of the Company's current and former directors and officers, and the underwriters of the Company's IPO, and alleging claims under Section 15 of the Securities Act against the Company and certain of the Company's current and former directors and officers. |
◦ | On or about November 30, 2016, a substantially similar class action was commenced in the Massachusetts Superior Court, Suffolk County, by a different plaintiff (Civ. Action No. 16-3670) alleging claims under Sections 11 and 15 of the Securities Act against the same defendants as in the action commenced on October 31, 2016, and also alleging claims under Section 12(a)(2) of the Securities Act against the Company, certain of the Company's current and former directors and officers, and the underwriters of the Company's IPO. This action was ordered consolidated in the Massachusetts Superior Court, Suffolk County on January 9, 2017 with the action commenced on October 31, 2016, and the two actions are referred to as the “Consolidated Massachusetts State Court Actions”. The plaintiffs in the Consolidated Massachusetts State Court Actions filed a consolidated amended complaint on March 20, 2017. The Company moved to dismiss the Consolidated Massachusetts State Court Actions on June 2, 2017. For more information, see Note 11. |
◦ | On or about January 31, 2017, a substantially similar class action was commenced in the United States District Court for the District of Massachusetts (Case No. 1:17-cv-10169) by four of the same plaintiffs who commenced the California State Court Actions, and two additional plaintiffs, alleging claims under Sections 11 and 12(a)(2) of the Securities Act against the Company, certain of the Company's current and former directors and officers, and the underwriters of the Company's IPO, and alleging claims under Section 15 of the Securities Act against certain of the Company's current and former directors and officers. This action is referred to as the “Massachusetts Federal Court Action.” On July 6, 2017, the Company moved to stay the Massachusetts Federal Court Action. The plaintiffs in the Massachusetts Federal Court Action filed a consolidated amended complaint on August 9, 2017. For more information, see Note 11. |
a. | Share option plans: |
Nine Months Ended September 30, | ||||
2017 | 2016 | |||
Expected volatility | 56% - 58% | 53% - 60% | ||
Risk-free rate | 1.78% - 2.07% | 1.16%-1.60% | ||
Dividend yield | —% | —% | ||
Expected term (in years) | 5.31-6.11 | 5.31-6.11 | ||
Share price | $1.3- $2.1 | $6.8- $11.88 |
Nine Months Ended September 30, 2017 | ||||||||||||
Number | Average exercise price | Average remaining contractual life (in years) (1) | Aggregate intrinsic value (in thousands) | |||||||||
Options and RSUs outstanding at the beginning of the period | 2,251,014 | $ | 6.47 | 7.80 | $ | 1,740 | ||||||
Options granted | 413,746 | 2.01 | ||||||||||
RSUs granted | 230,484 | — | ||||||||||
Options exercised (2) | (30,192 | ) | 1.39 | |||||||||
RSUs vested (2) | (59,450 | ) | — | |||||||||
RSUs forfeited | (44,196 | ) | — | |||||||||
Options forfeited | (169,008 | ) | 2.99 | |||||||||
Options and RSUs outstanding at the end of the period | 2,592,398 | $ | 5.39 | 7.45 | $ | 578 | ||||||
Options exercisable at the end of the period | 1,272,727 | $ | 6.12 | 6.46 | $ | 64 |
(1) | Calculation of weighted average remaining contractual term does not include RSUs, which have an indefinite contractual term. |
(2) | During the nine months period ended September 30, 2017, the aggregate number of ordinary shares that were issued pursuant to RSUs that became vested and options that were exercised on a net basis was 87,795 ordinary shares. |
Range of exercise price | Options and RSUs outstanding as of September 30, 2017 | Weighted average remaining contractual life (years) (1) | Options exercisable as of September 30, 2017 | Weighted average remaining contractual life (years) (1) | ||||||||
RSUs only | 353,437 | — | — | — | ||||||||
$0.82 | 31,803 | 3.29 | 31,803 | 3.29 | ||||||||
$1.32 | 335,095 | 4.75 | 330,095 | 4.67 | ||||||||
$1.47 - $2.20 | 762,937 | 8.07 | 338,830 | 6.35 | ||||||||
$6.80- $8.99 | 663,382 | 8.09 | 322,536 | 7.96 | ||||||||
$9.22- $10.98 | 201,343 | 8.42 | 75,586 | 8.10 | ||||||||
$19.62-$20.97 | 244,401 | 7.17 | 173,877 | 7.15 | ||||||||
2,592,398 | 7.45 | 1,272,727 | 6.46 |
(1) | Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term. |
b. | Share-based awards to non-employee consultants: |
c. | Warrants to purchase ordinary shares: |
Issuance date | Warrants outstanding | Exercise price per warrant | Warrants exercisable | Contractual term | |||||||
(number) | (number) | ||||||||||
July 14, 2014 (1) | 403,804 | $ | 10.08 | 403,804 | July 13, 2018 | ||||||
December 30, 2015 (2) | 119,295 | $ | 9.64 | 119,295 | See footnote (2) | ||||||
November 1, 2016 (3) | 2,437,500 | $ | 4.75 | 2,437,500 | November 1, 2021 | ||||||
December 28, 2016 (4) | 47,717 | $ | 9.64 | 47,717 | See footnote (4) | ||||||
3,008,316 | 3,008,316 |
(1) | Represents warrants to purchase ordinary shares at an exercise price of $10.08 per share, which were granted on July 14, 2014 as part of our series E investment round. |
(2) | Represents a warrant to purchase ordinary shares at an exercise price of $9.64 per share, which was issued on December 31, 2015 to Kreos, in connection with a loan made by Kreos to us. The warrant is currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of September 30, 2017. |
(3) | Represents warrants issued as part of our follow-on offering in November 2016. |
(4) | Represents a warrant in the amount of 47,717 ordinary shares issued to Kreos as part of the $8.0 million drawdown under the Loan Agreement, which occurred on December 28, 2016. See footnote 2 above for exercisability terms. |
d. | Share-based compensation expense for employees and non-employees: |
Nine Months Ended September 30, | |||||||
2017 | 2016 | ||||||
Cost of revenues | $ | 57 | $ | 78 | |||
Research and development, net | 344 | 398 | |||||
Sales and marketing, net | 585 | 606 | |||||
General and administrative | 1,611 | 1,376 | |||||
Total | $ | 2,597 | $ | 2,458 |
e. | At-the-market offering program: |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2017 | 2016 | 2017 | 2016 | ||||||||||||
Foreign currency transactions and other | $ | (37 | ) | $ | 17 | $ | (113 | ) | $ | 60 | |||||
Financial expenses related to loan agreement with Kreos | 510 | 495 | 1,932 | 1,462 | |||||||||||
Bank commissions | 6 | 5 | 24 | 28 | |||||||||||
Income related to hedging transactions | — | (9 | ) | — | (36 | ) | |||||||||
$ | 479 | $ | 508 | $ | 1,843 | $ | 1,514 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2017 | 2016 | 2017 | 2016 | ||||||||||||
Revenues based on customer’s location: | |||||||||||||||
Israel | $ | — | $ | — | $ | — | $ | — | |||||||
United States | 801 | 710 | 4,242 | 2,976 | |||||||||||
Europe | 931 | 404 | 1,996 | 908 | |||||||||||
Asia-Pacific | — | 286 | — | 394 | |||||||||||
Total revenues | $ | 1,732 | $ | 1,400 | $ | 6,238 | $ | 4,278 |
September 30, | December 31, | ||||||
2017 | 2016 | ||||||
Long-lived assets by geographic region (*): | |||||||
Israel | $ | 330 | $ | 476 | |||
United States | 361 | 565 | |||||
Germany | 215 | 217 | |||||
$ | 906 | $ | 1,258 |
September 30, | December 31, | ||||
2017 | 2016 | ||||
Customer A | 42.6 | % | 33.3 | % |
a. | Legal claims: class action litigation (see Note 5d) |
• | Consolidated Massachusetts State Court Actions: The court heard oral argument on the Company's’ motion to dismiss on October 16, 2017. |
• | Massachusetts Federal Court Action: The court denied the Company's motion to stay and has set the time for the Company's motion to dismiss to November 10, 2017. |
b. | Share option plans: Equity Exchange Program (see Note 8a) |
• | our expectations regarding future growth, including our ability to increase sales in our existing geographic markets expand to new markets and achieve our planned expense reductions; |
• | our management’s conclusion in the notes to our unaudited condensed consolidated financial statements included in this report and to our audited consolidated financial statements for fiscal 2016, and our independent registered public accounting firm’s statement in its opinion relating to our audited consolidated financial statements for fiscal 2016, that there are a substantial doubts as to our ability to continue as a going concern; |
• | our ability to maintain and grow our reputation and the market acceptance of our products; |
• | our ability to achieve reimbursement from third-party payors for our products; |
• | our expectations as to our clinical research program and clinical results; |
• | our expectations as to the results of and Food and Drug Administration’s (the "FDA") potential |
• | the outcome of ongoing shareholder class action litigation relating to our IPO; |
• | our ability to repay our secured indebtedness; |
• | our ability to improve our products and develop new products; |
• | our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others; |
• | our ability to gain and maintain regulatory approvals; |
• | our ability to secure capital from equity and debt financings in light of limitations under our Form S-3, |
• | our ability to use effectively the proceeds of any offerings of our securities; |
• | the impact of the market price of our ordinary shares on the determination of whether we are a passive foreign investment company; |
• | our ability to maintain relationships with existing customers and develop relationships with new customers. |
• | our ability to comply with the continued listing requirements of the NASDAQ Capital Market and the risk that our ordinary shares will be delisted if we cannot do so; and |
• | our compliance with medical device reporting regulations to report adverse events involving our products and the potential impact of such adverse events on our ability to market and sell its products. |
• | Revenues grew 24% to $1.7 million and 46% to $6.2 million for the three and nine months ended September 30, 2017, respectively, compared to revenues of $1.4 million and $4.3 million for the three and nine months ended September 30, 2016, respectively. |
• | We placed 16 ReWalk devices during the quarter ended September 30, 2017, of which 10 were placed in the Unites States, 3 were in our direct markets in Europe, and 3 were in other markets. |
• | We secured 7 favorable case by case insurance reimbursement decisions. |
• | We increased pending insurance claims to 218 in the U.S. and Germany, as of September 30, 2017, compared to 149 as of the end of the prior year period. |
• | Barmer confirmed it will provide ReWalk systems to all qualifying beneficiaries. Barmer provides insurance coverage for nearly ten million people in Germany, as a member of the German Statutory Health Insurance network and one of the most significant national insurers in the country. Exoskeletons will be provided to users that meet certain inclusion criteria and assessment by the German Health Insurance Medical Service (Medizinischer Dienst der Krankenversicherungen) before and after training. Barmer has already begun processing claims with users entering training for in-home use of an exoskeleton. |
• | Germany’s national social accident insurance provider, DGUV, signed a confirmation letter with ReWalk, stipulating that the DGUV's member payers, including the health insurance association Berufsgenossenschaft (also known as BG) and state insurers, will approve the supply of exoskeleton systems for qualifying beneficiaries on a case-by-case basis. DGUV is comprised of 35 different insurers, which provide coverage for more than 70 million individuals in Germany. Per the agreement, eligible individuals will go to BG clinics for evaluation as a part of the procurement. |
• | Completed critical design review processes and began the pre-clinical testing of the Restore lightweight soft-exosuit base design in preparation for the clinical study and commercialization of an initial indication designed for stroke patients. |
• | Total operating expenses in the third quarter of 2017 were $6.1 million, compared with $7.7 million in the prior year period. The reduction in operating expenses reflected our initiatives to reduce spending, as announced earlier in 2017. |
• | During the quarter ended September 30, 2017, we sold 1,678,288 shares generating total net proceeds to the Company of $2.9 million (after commissions, fees and expenses) under our ATM Offering Program. For more information, see Note 8e to our unaudited condensed consolidated financial statements set forth in “Part I, Item 1. Financial Statements” above and “Liquidity and Capital Resources” below. |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2017 | 2016 | 2017 | 2016 | ||||||||||||
Revenues | $ | 1,732 | $ | 1,400 | $ | 6,238 | $ | 4,278 | |||||||
Cost of revenues | 1,024 | 1,110 | 3,740 | 3,410 | |||||||||||
Gross profit | 708 | 290 | 2,498 | 868 | |||||||||||
Operating expenses: | |||||||||||||||
Research and development, net | 1,618 | 1,968 | 4,433 | 6,737 | |||||||||||
Sales and marketing | 2,637 | 3,774 | 8,643 | 10,577 | |||||||||||
General and administrative | 1,805 | 1,951 | 5,796 | 5,960 | |||||||||||
Total operating expenses | 6,060 | 7,693 | 18,872 | 23,274 | |||||||||||
Operating loss | (5,352 | ) | (7,403 | ) | (16,374 | ) | (22,406 | ) | |||||||
Loss on extinguishment of debt | — | — | 313 | — | |||||||||||
Financial expenses, net | 479 | 508 | 1,843 | 1,514 | |||||||||||
Loss before income taxes | (5,831 | ) | (7,911 | ) | (18,530 | ) | (23,920 | ) | |||||||
Income taxes | 15 | 9 | 25 | 39 | |||||||||||
Net loss | $ | (5,846 | ) | $ | (7,920 | ) | $ | (18,555 | ) | $ | (23,959 | ) | |||
Net loss per ordinary share, basic and diluted | $ | (0.27 | ) | $ | (0.62 | ) | $ | (1.00 | ) | $ | (1.92 | ) | |||
Weighted average number of shares used in computing net loss per ordinary share, basic and diluted | 21,660,757 | 12,759,887 | 18,463,444 | 12,495,433 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2017 | 2016 | 2017 | 2016 | ||||||||||||
(in thousands, except unit amounts) | (in thousands, except unit amounts) | ||||||||||||||
Personal units placed | 15 | 20 | 81 | 75 | |||||||||||
Rehabilitation units placed | 1 | 3 | 3 | 5 | |||||||||||
Total units placed | 16 | 23 | 84 | 80 | |||||||||||
Personal unit revenues | $ | 1,707 | $ | 1,250 | $ | 6,033 | $ | 3,929 | |||||||
Rehabilitation unit revenues | $ | 25 | $ | 150 | $ | 205 | $ | 349 | |||||||
Revenues | $ | 1,732 | $ | 1,400 | $ | 6,238 | $ | 4,278 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2017 | 2016 | 2017 | 2016 | ||||||||||||
Gross profit | $ | 708 | $ | 290 | $ | 2,498 | $ | 868 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2017 | 2016 | 2017 | 2016 | ||||||||||||
Research and development expenses, net | $ | 1,618 | $ | 1,968 | $ | 4,433 | $ | 6,737 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2017 | 2016 | 2017 | 2016 | ||||||||||||
Sales and marketing expenses | $ | 2,637 | $ | 3,774 | $ | 8,643 | $ | 10,577 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2017 | 2016 | 2017 | 2016 | ||||||||||||
General and administrative | $ | 1,805 | $ | 1,951 | $ | 5,796 | $ | 5,960 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2017 | 2016 | 2017 | 2016 | ||||||||||||
Financial expenses, net | $ | 479 | $ | 508 | $ | 1,843 | $ | 1,514 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2017 | 2016 | 2017 | 2016 | ||||||||||||
Income tax | $ | 15 | $ | 9 | $ | 25 | $ | 39 |
Nine Months Ended September 30, | |||||||
2017 | 2016 | ||||||
Net cash used in operating activities | $ | (17,072 | ) | $ | (20,200 | ) | |
Net cash used in investing activities | (19 | ) | (408 | ) | |||
Net cash provided by financing activities | 6,341 | 15,138 | |||||
Net cash flow | $ | (10,750 | ) | $ | (5,470 | ) |
Payments due by period (in dollars, in thousands) | |||||||||||||||||||
Contractual obligations | Total | Less than 1 year | 1-3 years | 3-5 years | More than 5 years | ||||||||||||||
Purchase obligations (1) | $ | 806 | $ | 806 | $ | — | $ | — | $ | — | |||||||||
Collaboration Agreement and License Agreement obligations (2) | 4,238 | 1,350 | 2,100 | 788 | — | ||||||||||||||
Operating lease obligations (3) | 4,251 | 636 | 1,173 | 1,190 | 1,252 | ||||||||||||||
Long-term debt obligations (4) | 19,288 | 5,663 | 13,625 | — | — | ||||||||||||||
Total | $ | 28,583 | $ | 8,455 | $ | 16,898 | $ | 1,978 | $ | 1,252 |
• | determining the composition of our board of directors, which has the authority to direct our business and to appoint and remove our officers; |
• | approving or rejecting a merger, consolidation or other business combination; |
• | raising future capital; and |
• | amending our Second Amended and Restated Articles of Association, as amended by the First Amendment thereto, which govern the rights attached to our ordinary shares. |
Exhibit Number | Description | |
31.1 | ||
31.2 | ||
32.1 | ||
32.2 | ||
101.INS | XBRL Instance Document | |
101.SCH | XBRL Taxonomy Extension Schema Document | |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document | |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document | |
101.LAB | XBRL Taxonomy Extension Label Linkbase Document | |
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
* | Furnished herewith. |
ReWalk Robotics Ltd. | ||
Date: November 2, 2017 | By: | /s/ Larry Jasinski |
Name: Larry Jasinski | ||
Title: Chief Executive Officer | ||
(Principal Executive Officer) | ||
Date: November 2, 2017 | By: | /s/ Kevin Hershberger |
Name: Kevin Hershberger | ||
Title: Chief Financial Officer | ||
(Principal Financial Officer and Principal Accounting Officer) |
/s/ Larry Jasinski | |
Larry Jasinski | |
Chief Executive Officer | |
(Principal Executive Officer) | |
ReWalk Robotics Ltd. |
/s/ Kevin Hershberger | |
Kevin Hershberger | |
Chief Financial Officer | |
(Principal Financial Officer) | |
ReWalk Robotics Ltd. |
• | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
• | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ Larry Jasinski | |
Larry Jasinski | |
Chief Executive Officer | |
(Principal Executive Officer) | |
ReWalk Robotics Ltd. |
• | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
• | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ Kevin Hershberger | |
Kevin Hershberger | |
Chief Financial Officer | |
(Principal Financial Officer) | |
ReWalk Robotics Ltd. |
Document and Entity Information - shares |
9 Months Ended | |
---|---|---|
Sep. 30, 2017 |
Oct. 31, 2017 |
|
Document and Entity Information [Abstract] | ||
Entity Registrant Name | ReWalk Robotics Ltd. | |
Entity Central Index Key | 0001607962 | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2017 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding (in shares) | 22,066,352 | |
Document Fiscal Year Focus | 2017 | |
Document Fiscal Period Focus | Q3 |
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - ₪ / shares |
Sep. 30, 2017 |
Dec. 31, 2016 |
---|---|---|
Statement of Financial Position [Abstract] | ||
Ordinary shares, par value (in ILS per share) | ₪ 0.01 | ₪ 0.01 |
Ordinary shares, shares authorized (in shares) | 250,000,000 | 250,000,000 |
Ordinary shares, shares issued (in shares) | 21,823,771 | 16,338,257 |
Ordinary shares, shares outstanding (in shares) | 21,823,771 | 16,338,257 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
Income Statement [Abstract] | ||||
Revenues | $ 1,732 | $ 1,400 | $ 6,238 | $ 4,278 |
Cost of revenues | 1,024 | 1,110 | 3,740 | 3,410 |
Gross profit | 708 | 290 | 2,498 | 868 |
Operating expenses: | ||||
Research and development, net | 1,618 | 1,968 | 4,433 | 6,737 |
Sales and marketing | 2,637 | 3,774 | 8,643 | 10,577 |
General and administrative | 1,805 | 1,951 | 5,796 | 5,960 |
Total operating expenses | 6,060 | 7,693 | 18,872 | 23,274 |
Operating loss | (5,352) | (7,403) | (16,374) | (22,406) |
Loss on extinguishment of debt | 0 | 0 | 313 | 0 |
Financial expenses, net | 479 | 508 | 1,843 | 1,514 |
Loss before income taxes | (5,831) | (7,911) | (18,530) | (23,920) |
Income taxes | 15 | 9 | 25 | 39 |
Net loss | $ (5,846) | $ (7,920) | $ (18,555) | $ (23,959) |
Net loss per ordinary share, basic and diluted (in USD per share) | $ (0.27) | $ (0.62) | $ (1.00) | $ (1.92) |
Weighted average number of shares used in computing net loss per ordinary share, basic and diluted (in shares) | 21,660,757 | 12,759,887 | 18,463,444 | 12,495,433 |
CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) $ in Thousands |
12 Months Ended |
---|---|
Dec. 31, 2016
USD ($)
| |
ATM Offering Program | Ordinary Share | |
Issuance costs | $ 468 |
Follow On Public Offering | Ordinary Share | |
Issuance costs | $ 1,099 |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands |
9 Months Ended | |||
---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
|||
Cash flows from operating activities: | ||||
Net loss | $ (18,555) | $ (23,959) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||
Depreciation | 516 | 503 | ||
Share-based compensation to employees and non- employees | 2,597 | 2,458 | ||
Deferred taxes | (20) | (64) | ||
Loss on extinguishment of debt | 313 | 0 | ||
Financial expenses related to long term loan | 87 | 495 | ||
Changes in assets and liabilities: | ||||
Trade receivables, net | (11) | 1,202 | ||
Prepaid expenses and other current and long term assets | (556) | (804) | ||
Inventories | (381) | (1,004) | ||
Trade payables | (1,048) | 960 | ||
Employees and payroll accruals | (161) | (285) | ||
Deferred revenues and advances from customers | 45 | 116 | ||
Other current and long term liabilities | 102 | 182 | ||
Net cash used in operating activities | (17,072) | (20,200) | ||
Cash flows from investing activities: | ||||
Purchase of property and equipment | (19) | (408) | ||
Net cash used in investing activities | (19) | (408) | ||
Cash flows from financing activities: | ||||
Issuance of ordinary shares upon exercise of options to purchase ordinary shares by employees and non-employees | 28 | 23 | ||
Proceeds from long term loan | 0 | 12,000 | ||
Debt issuance cost | 0 | (441) | ||
Repayment of long term loan | (2,747) | (554) | ||
Issuance of ordinary shares in at-the-market offering, net of issuance expenses paid in the amount of 389$ | [1] | 9,060 | 4,110 | |
Net cash provided by financing activities | 6,341 | 15,138 | ||
Decrease in cash and cash equivalents | (10,750) | (5,470) | ||
Cash and cash equivalents at beginning of period | 23,678 | 17,869 | ||
Cash and cash equivalents at end of period | 12,928 | 12,399 | ||
Supplemental disclosures of non-cash flow information | ||||
At-the-market offering expenses not yet paid | 50 | 11 | ||
Classification of inventory to property and equipment, net | $ 145 | $ 113 | ||
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) $ in Thousands |
9 Months Ended |
---|---|
Sep. 30, 2017
USD ($)
| |
Statement of Cash Flows [Abstract] | |
Issuance expenses | $ 389 |
GENERAL |
9 Months Ended | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||||||||||||||||||
GENERAL | GENERAL
The Company intends to finance operating costs over the next twelve months with existing cash on hand, reductions in operating spend, issuances under the Company's ATM Offering Program or other future issuances of equity and debt securities, or through a combination of the foregoing. However, the Company will need to seek additional sources of financing if the Company require more funds than anticipated during the next 12 months or in later periods. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. The condensed consolidated financial statements for the three and nine months ended September 30, 2017 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern. |
UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS |
9 Months Ended |
---|---|
Sep. 30, 2017 | |
Accounting Policies [Abstract] | |
UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS | UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles and standards of the Public Company Accounting Oversight Board for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, the accompanying financial statements include all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Company's (i) consolidated financial position as of September 30, 2017, (ii) consolidated results of operations for the three and nine months ended September 30, 2017 and (iii) consolidated cash flows for the nine months ended September 30, 2017. The results for the three and nine months periods ended September 30, 2017, as applicable, are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. |
SIGNIFICANT ACCOUNTING POLICIES |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||
SIGNIFICANT ACCOUNTING POLICIES | SIGNIFICANT ACCOUNTING POLICIES
Recently Implemented Accounting Pronouncements Inventory - In July 2015, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2015-11, “Simplifying the Measurement of Inventory.” The standard changes the inventory valuation method from the lower of cost or market to the lower of cost or net realizable value for inventory valued under the first-in, first-out or average cost methods. This standard is effective for fiscal years beginning after December 15, 2016, including interim periods and requires prospective adoption with early adoption permitted. The update was effective for the Company beginning January 1, 2017. The adoption of this standard did not materially impact the Company's financial statements. Deferred Taxes - In November 2015, the FASB issued ASU 2015-17, “Balance Sheet Classification of Deferred Taxes", which simplifies the presentation of deferred income taxes. ASU 2015-17 provides presentation requirements to classify deferred tax assets and liabilities, along with any related valuation allowance, as noncurrent on the balance sheet. The standard is effective for fiscal years beginning after December 15, 2016, including interim periods within that reporting period. The Company elected to implement this ASU-2015-17 prospectively. The update was effective for the Company beginning January 1, 2017. The adoption of this standard did not materially impact the Company's financial statements. Recent Accounting Pronouncements Not Yet Adopted Revenues - In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance, including industry-specific guidance. The core principle is that an entity will recognize revenue to depict the transfer of goods or services to customers in an amount that the entity expects to be entitled to in exchange for those goods or services. The standard provides a five-step model to determine when and how revenue is recognized. Other major provisions of the standard include capitalization of certain contract costs, consideration of time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The standard also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. The guidance permits two methods of adoption: the full retrospective method, in which case the standard would be applied to each prior reporting period presented and the cumulative effect of applying the standard would be recognized at the earliest period shown, or the modified retrospective transition method, in which case the cumulative effect of applying the standard would be recognized at the date of initial application. The Company has substantially completed its evaluation of significant contracts and the review of its current accounting policies and practices to identify potential differences that would result from applying the requirements of the new standard to the Company’s revenue contracts. In addition, the Company is in the process of identifying the appropriate changes to business processes, systems and controls to support recognition and disclosure under the new standard. While a final decision has not been made, the Company expects to adopt the new revenue standard in the first quarter of 2018 applying the modified retrospective transition method. The Company does not expect the adoption of the new revenue standard to have a material impact on the amount and timing of revenue recognized in the Company's consolidated financial statements. Leases - In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). Under the new guidance, a lessee will be required to recognize assets and liabilities for all leases with lease terms of more than 12 months. Consistent with current generally accepted accounting principles, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. This ASU requires additional disclosures. The standard is effective for annual periods beginning after December 15, 2018 and interim periods within those fiscal years. The ASU requires adoption based upon a modified retrospective transition approach. Early adoption is permitted. The Company has not yet determined whether it will elect early adoption and is currently evaluating the impact of the pending adoption of this ASU on the Company's consolidated financial statements and related disclosures. Statement of Cash Flows - In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments.” The standard addresses several matters of diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows including the presentation of debt extinguishment costs and distributions received from equity method investments. The standard is effective for fiscal years beginning after December 15, 2017, including interim periods and allows for retrospective adoption with early adoption permitted. The Company has chosen not to adopt this standard early, and does not expect the adoption of the standard to have a material impact on the Company's consolidated financial statements. Statement of Cash Flows - On November 17, 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force).” This ASU requires the statement of cash flows to explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents are to be included with cash and cash equivalents when reconciling the beginning of period and end of period amounts shown on the statement of cash flows. ASU No. 2016-18 will be effective for the Company as of January 1, 2018. The Company does not expect the adoption of this ASU to have a material impact on the Company's consolidated financial statements. Share Based Compensation - On May 10, 2017, the FASB issued ASU 2017-09, “Compensation - Stock Compensation (Topic 718), Scope of Modification Accounting.” This ASU clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. Entities will apply the modification accounting guidance if the value, vesting conditions or classification of the award changes. They will have to make all of the disclosures about modifications that are required today, in addition to disclosing that compensation expense has not changed, to the extent applicable. The ASU also clarifies that a modification to an award could be significant and therefore require disclosure, even if modification accounting is not required. ASU No. 2017-09 will be effective for fiscal years beginning after December 15, 2017. Early adoption is permitted, including in any interim period for which financial statements have not yet been issued or made available for issuance. The ASU will be applied prospectively to awards modified on or after the adoption date. The Company is currently evaluating the impact of the pending adoption of this ASU on its consolidated financial statements and related disclosures.
Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales. One customer represented 12.7% and 0% of the Company's trade receivable, net balance as of September 30, 2017 and December 31, 2016, respectively. A second customer represented 12.3% and 4.9% of the Company's trade receivable, net balance as of September 30, 2017 and December 31, 2016, respectively. Trade receivables are presented net of allowance for doubtful accounts in the amount of $125 thousand and $333 thousand, respectively and net of sales return reserve of $105 thousand as of September 30, 2017 and December 31, 2016.
The Company provides a two-year standard warranty for its products. The Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair.
|
INVENTORY |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||
INVENTORY | INVENTORY The components of inventory are as follows (in thousands):
|
COMMITMENTS AND CONTINGENT LIABILITIES |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||
COMMITMENTS AND CONTINGENT LIABILITIES | COMMITMENTS AND CONTINGENT LIABILITIES
The Company has contractual obligations to purchase goods from its contract manufacturer, Sanmina Corporation. Purchase obligations do not include contracts that may be canceled without penalty. As of September 30, 2017, non-cancelable outstanding obligations amounted to approximately $806 thousand.
The Company’s research and development efforts are financed, in part, through funding from the Israel Innovation Authority (the “IIA”) (formerly known as the Israeli Office of the Chief Scientist in the Israel Ministry of Economy). During the nine months ended September 30, 2017 the Company received $828 thousand from the IIA to fund its research and development efforts. Since the Company’s inception through September 30, 2017, the Company received funding from the IIA in the total amount of $1.6 million. Out of the $1.6 million in funding from the IIA, a total amount of $1.2 million were royalty bearing grants (as of September 30, 2017, the Company paid royalties to the IIA in the total amount of $50 thousand), while a total amount of $400 thousand was received in consideration of 5,237 convertible preferred A shares, which converted after our initial public offering in September 2014 into ordinary shares in a conversion ratio of 1 to 1. The Company is obligated to pay royalties to the IIA, amounting to 3%-3.5% of the sales of the products and other related revenues generated from such projects, up to 100% of the grants received. As of September 30, 2017, the contingent liability to the IIA amounted to $1.1 million.
As discussed in Note 6 to our audited consolidated financial statements included in the Company's annual report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on February 17, 2017, as amended on Form 10-K/A filed with the SEC on April 27, 2017 (the “2016 Form 10-K”), the Company is party to the Loan Agreement with Kreos pursuant to which Kreos extended a $20 million line of credit to the Company. In connection with the Loan Agreement, the Company granted Kreos a first priority security interest over all of its assets, including intellectual property and equity interests in its subsidiaries, subject to certain permitted security interests. The Company's other long-term assets, which were in the amount of $850 thousand as of September 30, 2017, have been pledged as security in respect of a guarantee granted to a third party. Such deposit cannot be pledged to others or withdrawn without the consent of such third party.
Occasionally the Company is involved in various claims, lawsuits, regulatory examinations, investigations and other legal matters arising, for the most part, in the ordinary course of business. The outcome of litigation and other legal matters is inherently uncertain. In making a determination regarding accruals, using available information, the Company evaluates the likelihood of an unfavorable outcome in legal or regulatory proceedings to which the Company is a party and records a loss contingency when it is probable a liability has been incurred and the amount of the loss can be reasonably estimated. Where the Company determines an unfavorable outcome is not probable or reasonably estimable, the Company does not accrue for any potential litigation loss. These subjective determinations are based on the status of such legal or regulatory proceedings, the merits of our defenses, and consultation with legal counsel. Actual outcomes of these legal and regulatory proceedings may materially differ from the Company’s current estimates. It is possible that resolution of one or more of the legal matters currently pending or threatened could result in losses material to the Company’s consolidated results of operations, liquidity or financial condition. As set forth below, between September 2016 and January 2017, eight substantially similar putative securities class actions were filed against the Company. Four of these actions have been dismissed on procedural grounds, one was voluntarily dismissed and three are pending, including two actions which have been consolidated and one action brought by the plaintiffs whose actions were dismissed.
The complaints in all of the actions listed above allege that the Company's registration statement used in connection with its IPO failed to disclose that the Company was unprepared or unable to comply with certain regulatory special controls and to provide the FDA with a postmarket surveillance study on the Company's ReWalk Personal device, and that, as a result of such alleged omission, the plaintiffs suffered damages. The Massachusetts Federal Court Action also alleges that certain statements issued by the Company after its IPO are materially misleading because they omitted certain information. The Company believes that the allegations made in the complaints are without merit and intends to defend itself vigorously against the complaints relating to the three pending actions. Based on information currently available and the early stage of the litigation, the Company is unable to reasonably estimate a possible loss or range of possible losses, if any, with regard to these lawsuits; therefore, no litigation reserve has been recorded in the Company's consolidated balance sheet as of September 30, 2017. The Company will continue to evaluate information as it becomes known and will record an estimate for losses at the time or times when it is probable that a loss will be incurred and the amount of the loss is reasonably estimable. |
LOAN AGREEMENT WITH KREOS AND RELATED WARRANT TO PURCHASE ORDINARY SHARES |
9 Months Ended |
---|---|
Sep. 30, 2017 | |
Debt Disclosure [Abstract] | |
LOAN AGREEMENT WITH KREOS AND RELATED WARRANT TO PURCHASE ORDINARY SHARES | LOAN AGREEMENT WITH KREOS AND RELATED WARRANT TO PURCHASE ORDINARY SHARES On December 30, 2015, the Company entered into the loan agreement (the "Loan Agreement") with Kreos Capital V (Expert Fund) Limited ("Kreos"), pursuant to which Kreos extended a line of credit to the Company in the amount of $20 million. For more information, see Note 6 to our audited consolidated financial statements included in our 2016 Form 10-K. On June 9, 2017, the Company and Kreos entered into the First Amendment of the Loan Agreement (the "Loan Amendment"). As of that date the outstanding principal amount under the Loan Agreement (the "Outstanding Principal Amount") was $17.2 million. Under the Loan Amendment $3 million of the Outstanding Principal Amount was extended by an additional 3 years with the same interest rate and became subject to repayment in accordance with, and subject to the terms of, a secured convertible promissory note (the "Kreos Convertible Note"). The Kreos Convertible Note may be converted into up to 2,523,660 ordinary shares of the Company at a fixed conversion price of $1.268 per share (subject to customary antidilution adjustments in connection with a share split, reverse share split, share dividend, combination, reclassification or otherwise), thus reducing the Outstanding Principal Amount by $3 million to $14.2 million. Kreos may convert the then-outstanding principal under the Kreos Convertible Note in whole or in part, in one or more occasions, at any time until the earlier of (i) the maturity date of June 9, 2020 or (ii) a "Change of Control", as defined in the Loan Agreement. In addition, at any time until the maturity date of June 9, 2020, Kreos has the right to convert the “end of loan payments” under the Loan Agreement, in whole or in part, into ordinary shares at a conversion price of $1.268 per share. Because the aggregate amount the Company drew down under the Loan Agreement equals $20 million and the total “end of loan payments” equal $200 thousand, Kreos has the right to convert up to 157,729 additional ordinary shares (subject to customary anti-dilution adjustments), making the total number of ordinary shares issuable upon conversion of the Kreos Convertible Note 2,523,660 (subject to customary anti-dilution adjustments). The Outstanding Principal Amount under the Loan Agreement is not convertible and remains subject to repayment in accordance with the terms and conditions of the Loan Agreement, provided that such amount shall be repaid by the Company in accordance with an amended repayment schedule. The Company concluded that the exchange of the $3 million for the convertible promissory note is not a troubled debt restructuring under applicable accounting guidance because the lenders did not grant a concession. The modification was analyzed under ASC 470 Debt to determine if extinguishment accounting was applicable. Under ASC 470-50-40-10 a modification or an exchange that adds or eliminates a substantive conversion option as of the conversion date is always considered substantial and requires extinguishment accounting. Since this modification added a substantive conversion option, extinguishment accounting is applicable. The difference between the fair value of the new debt with the pre-modification carrying amount of the old debt represented a loss on extinguishment in the amount of $313 thousand. According to the Loan Agreement the repayment period will be extended to 36 months if the Company raises $20 million or more in connection with the issuance of shares of its capital stock (including debt securities convertible into shares of the Company’s capital stock). As of June 30, 2017 the Company had raised more than $20 million and therefore the repayment period was extended by an additional 12 months to 36 months. |
RESEARCH COLLABORATION AND LICENSE AGREEMENT |
9 Months Ended |
---|---|
Sep. 30, 2017 | |
Research and Development [Abstract] | |
RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT | RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT On May 16, 2016, the Company entered into a Research Collaboration Agreement (“Collaboration Agreement”) and an Exclusive License Agreement (“License Agreement”) with Harvard. Under the Collaboration Agreement, Harvard and the Company have agreed to collaborate on research regarding the development of lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, which are intended to treat stroke, multiple sclerosis, mobility limitations for the elderly and other medical applications. The Company has committed to pay in quarterly installments for the funding of this research, subject to a minimum funding commitment under applicable circumstances. The Collaboration Agreement will expire on May 16, 2021. Under the License Agreement, Harvard has granted the Company an exclusive, worldwide royalty-bearing license under certain patents of Harvard relating to lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, a royalty-free license under certain related know-how and the option to obtain a license under certain inventions conceived under the joint research collaboration. The License Agreement requires the Company to pay Harvard an upfront fee, reimbursements for expenses that Harvard incurred in connection with the licensed patents, royalties on net sales and several milestone payments contingent upon the achievement of certain product development and commercialization milestones. The License Agreement will continue in full force and effect until the expiration of the last-to-expire valid claim of the licensed patents. As of September 30, 2017, the Company did not achieve any of these milestones, and is evaluating the likelihood that the milestones will be achieved on a quarterly basis. Moreover, since such royalties are dependent on future product sales which are neither determinable nor reasonably estimable, these royalty payments are not recorded on the Company's condensed consolidated balance sheet as of September 30, 2017. The Company's total payment obligation under the Collaboration Agreement and the License Agreement is $6.3 million, some of which is subject to a minimum funding commitment under applicable circumstances as indicated above. The Company has recorded expenses in the amount of $465 thousand and $267 thousand during the three months period ended September 30, 2017 and September 30, 2016 respectively. The Company has recorded expenses in the amount of $1.2 million and $1.3 million during the nine months period ended September 30, 2017 and September 30, 2016 respectively. Those expenses are part of the total payment obligation indicated above, as research and development expenses related to the License Agreement and to the Collaboration Agreement. |
SHAREHOLDERS' EQUITY |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SHAREHOLDERS' EQUITY | SHAREHOLDERS’ EQUITY
As of September 30, 2017, and December 31, 2016, the Company had reserved 602,158 and 380,153 ordinary shares, respectively, for issuance to the Company’s and its affiliates’ respective employees, directors, officers and consultants pursuant to equity awards granted under the Company's 2014 Incentive Compensation Plan (the “2014 Plan”). Options to purchase ordinary shares generally vest over four years, with certain options to non-employee directors vesting quarterly over one year. Any option that is forfeited or canceled before expiration becomes available for future grants under the 2014 Plan. The fair value for options granted during the nine months ended September 30, 2017 and September 30, 2016 was estimated at the date of the grant using a Black-Scholes-Merton option pricing model with the following assumptions:
The fair value of restricted share units (“RSUs”) granted is determined based on the price of the Company's ordinary shares on the date of grant. A summary of employee options to purchase ordinary shares and RSUs during the nine months ended September 30, 2017 is as follows:
The weighted average grant date fair value of options granted during the nine months ended September 30, 2017 and September 30, 2016 was $1.10 and $4.75, respectively. The weighted average grant date fair value of RSUs granted during the nine month period ended September 30, 2017 and September 30, 2016 was $2.01 and $9.28, respectively. The aggregate intrinsic value in the table above represents the total intrinsic value that would have been received by the option holders had all option holders that hold options with positive intrinsic value exercised their options on the last date of the exercise period. Total intrinsic value of options exercised for each of the nine months ended September 30, 2017 and September 30, 2016 was $29 thousand and $844 thousand respectively. As of September 30, 2017, there were $5.1 million of total unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Company's 2012 Equity Incentive Plan and its 2014 Plan. This cost is expected to be recognized over a period of approximately 2.1 years. The number of options and RSUs outstanding as of September 30, 2017 is set forth below, with options separated by range of exercise price. The below does not reflect the results of the Equity Exchange Program (as defined below) completed on October 5, 2017.
On September 6, 2017, the Company commenced a one-time equity award exchange program (the “Equity Exchange Program”), offering to certain eligible employees, executive officers and consultants the opportunity to cancel certain outstanding “underwater” stock options issued under the 2014 Plan, in exchange for the grant under such plan of a lesser number of RSUs. The Company's non-employee directors and retirees were not eligible to participate in the Equity Exchange Program. The Company conducted the Equity Exchange Program as a “value-for-value” exchange, pursuant to which the Company issued new RSUs with a value approximately equal to the value of the options that are surrendered, in accordance with the terms approved by the Company’s shareholders at the annual meeting of shareholders held on June 27, 2017. The primary purpose of the Equity Exchange Program was to restore the intended retention and incentive value of certain employee and consultant equity awards. Participation in the Equity Exchange Program was voluntary. The Company used the 52-week high closing price of its ordinary shares (as measured at the commencement of the Equity Exchange Program) as a threshold for options eligible to be exchanged. For more information on the results of the Equity Exchange Program, see Note 11.
The Company granted 3,454 options to a non-employee consultant on March 12, 2007, which were exercised during the nine months ended September 30, 2017. The Company granted 14,357 fully vested RSUs during the nine months ended September 30, 2017 to non-employee consultants. As of September 30, 2017, there are no outstanding options or RSUs held by non-employee consultants.
The following table summarizes information about warrants outstanding and exercisable as of September 30, 2017:
The Company recognized non-cash share-based compensation expense for both employees and non-employees in the consolidated statements of operations for the periods shown below as follows (in thousands):
On May 10, 2016, the Company entered into an equity distribution agreement (the “Equity Distribution Agreement”) with Piper Jaffray, pursuant to which it may offer and sell, from time to time, ordinary shares having an aggregate offering price of up to $25 million, through Piper Jaffray acting as its agent. Subject to the terms and conditions of the Equity Distribution Agreement, Piper Jaffray will use its commercially reasonable efforts to sell on the Company’s behalf all of the ordinary shares requested to be sold by the Company, consistent with its normal trading and sales practices. Piper Jaffray may also act as principal in the sale of ordinary shares under the Equity Distribution Agreement. Sales may be made under the Company's Form S-3, in what may be deemed “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “ATM Offering Program”). Sales may be made directly on or through the NASDAQ Capital Market, the existing trading market for the Company's ordinary shares, to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or any other method permitted by law, including in privately negotiated transactions. Piper Jaffray is entitled to compensation at a fixed commission rate of 3.0% of the gross sales price per share sold through it as agent under the Equity Distribution Agreement. Where Piper Jaffray acts as principal in the sale of ordinary shares under the Equity Distribution Agreement, such rate of compensation will not apply, but in no event will the total compensation of Piper Jaffray, when combined with the reimbursement of Piper Jaffray for the out-of-pocket fees and disbursements of its legal counsel, exceed 8.0% of the gross proceeds received from the sale of the ordinary shares. The Company is not required to sell any of its ordinary shares at any time. The Company may raise up to $25 million under its ATM Offering Program pursuant to the terms of its agreement with the sales agent. However, due to limitations under the rules of Form S-3, which have applied to the Company since it filed its annual report on Form 10-K for the fiscal year ended December 31, 2016 on February 17, 2017, taking into account ordinary shares issued and settled under the Company’s ATM Offering Program since February 17, 2017, as of September 30, 2017, the Company may issue up to $4.3 million in primary offerings under its effective shelf registration statement on Form S-3 (File No. 333- 209833), including its ATM Offering Program, during the 12 months following February 17, 2017, unless and until it is no longer subject to such limitations. During the nine months ended September 30, 2017, the Company issued and sold 5,379,908 ordinary shares at an average price of $1.76 per share under its ATM Offering Program. The gross proceeds to the Company were $9.4 million, and the net aggregate proceeds after deducting commissions, fees and offering expenses in the amount of $439 thousand were $9.0 million. As a result, from the inception of the ATM Offering Program in May 2016 until September 30, 2017, the Company had sold 6,071,970 ordinary shares under the ATM Offering Program for gross proceeds of $14.0 million and net proceeds to the Company of $13.1 million (after commissions, fees and expenses). Additionally, as of that date, the Company had paid Piper Jaffray compensation of $420 thousand and had incurred total expenses of approximately $907 thousand in connection with the ATM Offering Program. |
FINANCIAL EXPENSES, NET |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Income and Expenses [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FINANCIAL EXPENSES, NET | FINANCIAL EXPENSES, NET The components of financial expenses, net were as follows (in thousands):
|
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA | GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA Summary information about geographic areas: ASC 280, “Segment Reporting” establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing the enterprise’s performance. The Company manages its business on the basis of one reportable segment, and derives revenues from selling systems and services (see Note 1 for a brief description of the Company’s business). The below is a summary of revenues within geographic areas (in thousands):
(*) Long-lived assets are comprised of property and equipment, net. Major customer data as a percentage of total revenues (in thousands):
|
SUBSEQUENT EVENTS |
9 Months Ended | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||
Subsequent Events [Abstract] | |||||||||||||||||
SUBSEQUENT EVENTS | SUBSEQUENT EVENTS
As of November 1, 2017, there were three pending class action lawsuits against the Company and certain other defendants alleging claims under the Securities Act in connection with the Company’s registration statement used in its IPO, including the Consolidated Massachusetts State Court Actions and the Massachusetts Federal Court Action. These actions are further described above in Note 5d.
On the Equity Exchange Program’s expiration date of October 4, 2017, 46 holders tendered options to purchase an aggregate of 945,416 ordinary shares, representing 96.4% of all options eligible for exchange, and on October 5, 2017, the Company granted to these holders an aggregate of 251,872 new RSUs. 180,167 of these new RSUs were granted to the Company’s executive officers and “named executive officers” (as defined in Item 402 of Regulation S-K of the SEC). Unless the Company’s compensation committee accelerates their vesting, the new RSUs vest over a three-year period, with one-third vesting on the first anniversary of the date of grant and one-third vesting on each of the next two successive anniversaries. Additionally, the forfeiture terms of the new RSUs are substantially the same as those that apply generally to previously-granted RSUs granted under the 2014 Plan. The Equity Exchange Program is further described above in Note 8a. The stock options exchanged pursuant to the Exchange Program were canceled and the ordinary shares underlying such options became available for issuance under the 2014 Plan. |
SIGNIFICANT ACCOUNTING POLICIES (Policies) |
9 Months Ended |
---|---|
Sep. 30, 2017 | |
Accounting Policies [Abstract] | |
Basis of Accounting | The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles and standards of the Public Company Accounting Oversight Board for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, the accompanying financial statements include all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Company's (i) consolidated financial position as of September 30, 2017, (ii) consolidated results of operations for the three and nine months ended September 30, 2017 and (iii) consolidated cash flows for the nine months ended September 30, 2017. The results for the three and nine months periods ended September 30, 2017, as applicable, are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements: Recently Implemented Accounting Pronouncements Inventory - In July 2015, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2015-11, “Simplifying the Measurement of Inventory.” The standard changes the inventory valuation method from the lower of cost or market to the lower of cost or net realizable value for inventory valued under the first-in, first-out or average cost methods. This standard is effective for fiscal years beginning after December 15, 2016, including interim periods and requires prospective adoption with early adoption permitted. The update was effective for the Company beginning January 1, 2017. The adoption of this standard did not materially impact the Company's financial statements. Deferred Taxes - In November 2015, the FASB issued ASU 2015-17, “Balance Sheet Classification of Deferred Taxes", which simplifies the presentation of deferred income taxes. ASU 2015-17 provides presentation requirements to classify deferred tax assets and liabilities, along with any related valuation allowance, as noncurrent on the balance sheet. The standard is effective for fiscal years beginning after December 15, 2016, including interim periods within that reporting period. The Company elected to implement this ASU-2015-17 prospectively. The update was effective for the Company beginning January 1, 2017. The adoption of this standard did not materially impact the Company's financial statements. Recent Accounting Pronouncements Not Yet Adopted Revenues - In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance, including industry-specific guidance. The core principle is that an entity will recognize revenue to depict the transfer of goods or services to customers in an amount that the entity expects to be entitled to in exchange for those goods or services. The standard provides a five-step model to determine when and how revenue is recognized. Other major provisions of the standard include capitalization of certain contract costs, consideration of time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The standard also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. The guidance permits two methods of adoption: the full retrospective method, in which case the standard would be applied to each prior reporting period presented and the cumulative effect of applying the standard would be recognized at the earliest period shown, or the modified retrospective transition method, in which case the cumulative effect of applying the standard would be recognized at the date of initial application. The Company has substantially completed its evaluation of significant contracts and the review of its current accounting policies and practices to identify potential differences that would result from applying the requirements of the new standard to the Company’s revenue contracts. In addition, the Company is in the process of identifying the appropriate changes to business processes, systems and controls to support recognition and disclosure under the new standard. While a final decision has not been made, the Company expects to adopt the new revenue standard in the first quarter of 2018 applying the modified retrospective transition method. The Company does not expect the adoption of the new revenue standard to have a material impact on the amount and timing of revenue recognized in the Company's consolidated financial statements. Leases - In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). Under the new guidance, a lessee will be required to recognize assets and liabilities for all leases with lease terms of more than 12 months. Consistent with current generally accepted accounting principles, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. This ASU requires additional disclosures. The standard is effective for annual periods beginning after December 15, 2018 and interim periods within those fiscal years. The ASU requires adoption based upon a modified retrospective transition approach. Early adoption is permitted. The Company has not yet determined whether it will elect early adoption and is currently evaluating the impact of the pending adoption of this ASU on the Company's consolidated financial statements and related disclosures. Statement of Cash Flows - In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments.” The standard addresses several matters of diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows including the presentation of debt extinguishment costs and distributions received from equity method investments. The standard is effective for fiscal years beginning after December 15, 2017, including interim periods and allows for retrospective adoption with early adoption permitted. The Company has chosen not to adopt this standard early, and does not expect the adoption of the standard to have a material impact on the Company's consolidated financial statements. Statement of Cash Flows - On November 17, 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force).” This ASU requires the statement of cash flows to explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents are to be included with cash and cash equivalents when reconciling the beginning of period and end of period amounts shown on the statement of cash flows. ASU No. 2016-18 will be effective for the Company as of January 1, 2018. The Company does not expect the adoption of this ASU to have a material impact on the Company's consolidated financial statements. Share Based Compensation - On May 10, 2017, the FASB issued ASU 2017-09, “Compensation - Stock Compensation (Topic 718), Scope of Modification Accounting.” This ASU clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. Entities will apply the modification accounting guidance if the value, vesting conditions or classification of the award changes. They will have to make all of the disclosures about modifications that are required today, in addition to disclosing that compensation expense has not changed, to the extent applicable. The ASU also clarifies that a modification to an award could be significant and therefore require disclosure, even if modification accounting is not required. ASU No. 2017-09 will be effective for fiscal years beginning after December 15, 2017. Early adoption is permitted, including in any interim period for which financial statements have not yet been issued or made available for issuance. The ASU will be applied prospectively to awards modified on or after the adoption date. The Company is currently evaluating the impact of the pending adoption of this ASU on its consolidated financial statements and related disclosures. |
Concentrations of Credit Risks | Concentrations of Credit Risks: Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales. One customer represented 12.7% and 0% of the Company's trade receivable, net balance as of September 30, 2017 and December 31, 2016, respectively. A second customer represented 12.3% and 4.9% of the Company's trade receivable, net balance a |
Warranty | Warranty provision The Company provides a two-year standard warranty for its products. The Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. |
SIGNIFICANT ACCOUNTING POLICIES (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||
Schedule of product warranty liability |
|
INVENTORY (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of inventories | The components of inventory are as follows (in thousands):
|
SHAREHOLDERS' EQUITY (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of stock option valuation assumptions | The fair value for options granted during the nine months ended September 30, 2017 and September 30, 2016 was estimated at the date of the grant using a Black-Scholes-Merton option pricing model with the following assumptions:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of stock option and RSU activity | A summary of employee options to purchase ordinary shares and RSUs during the nine months ended September 30, 2017 is as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of options and RSUs outstanding which have been separated into ranges of exercise price | The number of options and RSUs outstanding as of September 30, 2017 is set forth below, with options separated by range of exercise price. The below does not reflect the results of the Equity Exchange Program (as defined below) completed on October 5, 2017.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of warrants outstanding and exercisable | The following table summarizes information about warrants outstanding and exercisable as of September 30, 2017:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of non-cash share-based compensation expense | The Company recognized non-cash share-based compensation expense for both employees and non-employees in the consolidated statements of operations for the periods shown below as follows (in thousands):
|
FINANCIAL EXPENSES, NET (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Income and Expenses [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of financial expenses, net | The components of financial expenses, net were as follows (in thousands):
|
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of revenues within geographic areas | The below is a summary of revenues within geographic areas (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of long-lived assets by geographic region |
(*) Long-lived assets are comprised of property and equipment, net. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of major customer data as a percentage of total revenues | Major customer data as a percentage of total revenues (in thousands):
|
GENERAL (Details) $ in Thousands |
9 Months Ended | 12 Months Ended | |
---|---|---|---|
Sep. 30, 2017
USD ($)
subsidiary
|
Dec. 31, 2017 |
Dec. 31, 2016
USD ($)
|
|
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||
Number of wholly-owned subsidiaries | subsidiary | 2 | ||
Effects on Future Earnings and Cash Flows Resulting from Exit Plan [Line Items] | |||
Accumulated deficit | $ | $ 125,058 | $ 106,492 | |
Maximum | Scenario, Forecast | |||
Effects on Future Earnings and Cash Flows Resulting from Exit Plan [Line Items] | |||
Expected reduction in operating expenses | 30.00% |
GENERAL - ATM Offering Program (Details) - USD ($) |
9 Months Ended | 12 Months Ended | 17 Months Ended | |||||
---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 |
Dec. 31, 2016 |
Sep. 30, 2017 |
May 10, 2016 |
|||||
Class of Stock [Line Items] | ||||||||
Maximum amount which can be raised under ATM offering program | $ 25,000,000.0 | |||||||
Maximum amount which can be raised under shelf registration statement | $ 4,300,000.0 | $ 4,300,000.0 | ||||||
ATM Offering Program | ||||||||
Class of Stock [Line Items] | ||||||||
Gross proceeds from shares issued under the ATM offering program | 9,400,000 | 14,000,000 | ||||||
Underwriter commission, fees and offering expenses | 439,000 | 907,000 | ||||||
Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses | 9,010,000 | [1] | $ 4,099,000 | 13,100,000 | ||||
Maximum amount which can be raised under ATM offering program | 25,000,000 | 25,000,000 | ||||||
Maximum amount which can be raised under shelf registration statement | $ 4,300,000.0 | $ 4,300,000.0 | ||||||
ATM Offering Program | Weighted Average | ||||||||
Class of Stock [Line Items] | ||||||||
Price per share of shares sold under ATM offering program (in USD per share) | $ 1.76 | $ 2.31 | ||||||
Ordinary Share | ATM Offering Program | ||||||||
Class of Stock [Line Items] | ||||||||
Issuance of ordinary shares and warrants in an offering, net of issuance expenses (in shares) | 5,379,908 | [1] | 692,062 | 6,071,970 | [1] | |||
Underwriter commission, fees and offering expenses | $ 439,000 | [1] | $ 468,000 | |||||
Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses | $ 15,000 | [1] | $ 2,000 | |||||
|
GENERAL - Concentration Risk (Details) - Vendor concentration - Trade payables - manufacturer |
Sep. 30, 2017 |
Dec. 31, 2016 |
---|---|---|
Concentration Risk [Line Items] | ||
Number of contract manufacturers | 1 | 1 |
Concentration risk (as a percent) | 0.00% | 12.00% |
SIGNIFICANT ACCOUNTING POLICIES (Concentrations of Credit Risks) (Details) - USD ($) $ in Thousands |
9 Months Ended | 12 Months Ended |
---|---|---|
Sep. 30, 2017 |
Dec. 31, 2016 |
|
Concentration Risk [Line Items] | ||
Allowance for doubtful accounts | $ 125 | $ 333 |
Sales return reserve | $ 105 | $ 105 |
Customer A | Credit Concentration Risk | Trade Receivable | ||
Concentration Risk [Line Items] | ||
Concentration Risk, Percentage | 12.70% | 0.00% |
Customer B | Credit Concentration Risk | Trade Receivable | ||
Concentration Risk [Line Items] | ||
Concentration Risk, Percentage | 12.30% | 4.90% |
SIGNIFICANT ACCOUNTING POLICIES (Warranty Provision) (Details) $ in Thousands |
9 Months Ended |
---|---|
Sep. 30, 2017
USD ($)
| |
Accounting Policies [Abstract] | |
Standard warranty term | 2 years |
Movement in Standard Product Warranty Accrual [Roll Forward] | |
Balance at December 31, 2016 | $ 498 |
Provision | 311 |
Usage | (275) |
Balance at September 30, 2017 | $ 534 |
INVENTORY (Details) - USD ($) $ in Thousands |
Sep. 30, 2017 |
Dec. 31, 2016 |
---|---|---|
Inventory Disclosure [Abstract] | ||
Finished products | $ 3,500 | $ 3,264 |
Inventories | $ 3,500 | $ 3,264 |
COMMITMENTS AND CONTINGENT LIABILITIES (Narrative) (Details) |
2 Months Ended | 5 Months Ended | 9 Months Ended | 14 Months Ended | 195 Months Ended | ||
---|---|---|---|---|---|---|---|
Mar. 23, 2017
action
|
Nov. 10, 2016
action
|
Jan. 31, 2017
action
|
Sep. 30, 2017
USD ($)
action
shares
|
Nov. 03, 2017
action
|
Sep. 30, 2017
USD ($)
action
shares
|
Nov. 01, 2017
action
|
|
Commitments and Contingencies Disclosure [Abstract] | |||||||
Outstanding purchase orders | $ 806,000 | $ 806,000 | |||||
Other Commitments [Line Items] | |||||||
Collateral pledged | $ 850,000 | ||||||
Number of putative class actions brought against the company | action | 4 | 8 | |||||
Actions dismissed | action | 1 | ||||||
Actions pending | action | 3 | 3 | |||||
Litigation reserve | $ 0 | $ 0 | |||||
Subsequent Event | |||||||
Other Commitments [Line Items] | |||||||
Actions dismissed | action | 4 | ||||||
Actions pending | action | 3 | 3 | |||||
Subsequent Event | Consolidated Litigation | |||||||
Other Commitments [Line Items] | |||||||
Actions pending | action | 2 | ||||||
Subsequent Event | Plaintiff's Actions Dismissed | |||||||
Other Commitments [Line Items] | |||||||
Actions pending | action | 1 | ||||||
Term Loan | 10.75% Term Loan Due January 2019 | |||||||
Other Commitments [Line Items] | |||||||
Line of credit | 20,000,000.0 | 20,000,000.0 | |||||
IIA | |||||||
Other Commitments [Line Items] | |||||||
Total funding received | 828,000 | 1,600,000 | |||||
Royalty bearing grants | 1,200,000 | ||||||
Royalties paid | 50,000 | ||||||
Contingent liability | $ 1,100,000 | 1,100,000 | |||||
Series A Preferred Stock | IIA | |||||||
Other Commitments [Line Items] | |||||||
Amount received in consideration of preferred shares | $ 400,000 | ||||||
Issuance of ordinary shares (in shares) | shares | 5,237 | ||||||
Conversion ratio of preferred stock (in shares) | shares | 1 | 1 | |||||
Minimum | IIA | |||||||
Other Commitments [Line Items] | |||||||
Royalty (as a percent) | 3.00% | ||||||
Maximum | IIA | |||||||
Other Commitments [Line Items] | |||||||
Royalty (as a percent) | 3.50% | ||||||
Percentage of grant received considered to determine royalty fees | 100.00% |
LOAN AGREEMENT WITH KREOS AND RELATED WARRANT TO PURCHASE ORDINARY SHARES (Details) |
3 Months Ended | 9 Months Ended | ||||||
---|---|---|---|---|---|---|---|---|
Jun. 09, 2017
USD ($)
shares
$ / shares
|
Dec. 30, 2015
USD ($)
|
Sep. 30, 2017
USD ($)
|
Sep. 30, 2016
USD ($)
|
Sep. 30, 2017
USD ($)
|
Sep. 30, 2016
USD ($)
|
|||
Line of Credit Facility [Line Items] | ||||||||
Proceeds from long term loan | $ 0 | $ 12,000,000 | ||||||
Loss on extinguishment of debt | $ 0 | $ 0 | (313,000) | 0 | ||||
Issuance of ordinary shares in at-the-market offering, net of issuance expenses | [1] | 9,060,000 | $ 4,110,000 | |||||
Term Loan | ||||||||
Line of Credit Facility [Line Items] | ||||||||
Proceeds from long term loan | $ 20,000,000.0 | |||||||
Line of credit, outstanding principal | $ 17,200,000 | |||||||
Outstanding principal amount, portion of principal subject to extended repayment term | $ 3,000,000.0 | |||||||
Outstanding principal amount, extended repayment term | 36 months | |||||||
Number of equity securities debt instrument can be converted into (in shares) | shares | 2,523,660 | |||||||
Debt instrument, conversion price (in USD per share) | $ / shares | $ 1.268 | |||||||
Debt instrument, reduction in principal at conversion | $ 3,000,000 | |||||||
Debt instrument, outstanding principal amount not subject to conversion | 14,200,000 | |||||||
Debt instrument, end of loan payment | $ 200,000 | |||||||
Number of equity securities debt instrument can be converted into (in shares) | shares | 157,729 | |||||||
Loss on extinguishment of debt | $ 313,000 | |||||||
Proceeds from issuance of common stock required for repayment period to be extended | $ 20,000,000.0 | |||||||
Issuance of ordinary shares in at-the-market offering, net of issuance expenses | $ 20,000,000 | |||||||
Outstanding principal, increase to extended repayment term | 12 months | |||||||
|
RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||
Research and development, net | $ 1,618 | $ 1,968 | $ 4,433 | $ 6,737 |
Collaboration and Licensing Agreement | ||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||
Total payment obligation | 6,300 | 6,300 | ||
Research and development, net | $ 465 | $ 267 | $ 1,200 | $ 1,300 |
SHAREHOLDERS' EQUITY (Narrative - Share Option Plans) (Details) - USD ($) $ / shares in Units, $ in Thousands |
9 Months Ended | |||
---|---|---|---|---|
Jun. 27, 2017 |
Sep. 30, 2017 |
Sep. 30, 2016 |
Dec. 31, 2016 |
|
Shareholders' equity (deficiency) [Line Items] | ||||
Unrecognized compensation cost | $ 5,100 | |||
Period of recognition of unrecognized compensation cost | 2 years 1 month 17 days | |||
Options | ||||
Shareholders' equity (deficiency) [Line Items] | ||||
Shares reserved for future issuance (in shares) | 602,158 | 380,153 | ||
Award vesting period | 4 years | |||
Weighted average grant date fair value, options (in USD per share) | $ 1.10 | $ 4.75 | ||
Total intrinsic value of options exercised | $ 29 | $ 844 | ||
Number of options tendered (in shares) | 169,008 | |||
Options granted (in shares) | 413,746 | |||
Options | First anniversary of the date of grant | Exchange Program | ||||
Shareholders' equity (deficiency) [Line Items] | ||||
Vesting rights percentage | 33.33% | |||
Options | Second anniversary | Exchange Program | ||||
Shareholders' equity (deficiency) [Line Items] | ||||
Vesting rights percentage | 33.33% | |||
Options | Third anniversary | Exchange Program | ||||
Shareholders' equity (deficiency) [Line Items] | ||||
Vesting rights percentage | 33.33% | |||
Options | Non-employee Director | ||||
Shareholders' equity (deficiency) [Line Items] | ||||
Award vesting period | 1 year | |||
RSU | ||||
Shareholders' equity (deficiency) [Line Items] | ||||
Weighted average grant date fair value, restricted stock units (in USD per share) | $ 2.01 | $ 9.28 |
SHAREHOLDERS' EQUITY (Option Valuation Assumptions) (Details) - $ / shares |
9 Months Ended | |
---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
|
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Risk-free rate, minimum (as a percent) | 1.78% | 1.16% |
Risk-free rate, maximum (as a percent) | 2.07% | 1.60% |
Dividend yield | 0.00% | 0.00% |
Minimum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected volatility | 56.00% | 53.00% |
Expected term (in years) | 5 years 3 months 22 days | 5 years 3 months 22 days |
Share price (in USD per share) | $ 1.3 | $ 6.8 |
Maximum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected volatility | 58.00% | 60.00% |
Expected term (in years) | 6 years 1 month 10 days | 6 years 1 month 10 days |
Share price (in USD per share) | $ 2.1 | $ 11.88 |
SHAREHOLDERS' EQUITY (Summary of Employee Share Option and RSU Activity ) (Details) - USD ($) $ / shares in Units, $ in Thousands |
9 Months Ended | 12 Months Ended |
---|---|---|
Sep. 30, 2017 |
Dec. 31, 2016 |
|
Aggregate intrinsic value (in thousands) | ||
Issuance of ordinary share upon exercise of stock options and vesting of RSUs (in shares) | 87,795 | |
Stock Options and RSUs | ||
Number | ||
Options and RSU's outstanding at the beginning of the period (in shares) | 2,251,014 | |
Options and RSU's outstanding at the end of the period (in shares) | 2,592,398 | 2,251,014 |
Average exercise price | ||
Options and RSUs outstanding at the beginning of the period (in USD per share) | $ 6.47 | |
Options and RSUs outstanding at the end of the period (in USD per share) | $ 5.39 | $ 6.47 |
Average remaining contractual life (in years) | ||
Options and RSUs outstanding | 7 years 5 months 12 days | 7 years 9 months 18 days |
Aggregate intrinsic value (in thousands) | ||
Options and RSUs outstanding at beginning of the period | $ 1,740 | |
Options and RSUs outstanding at the end of the period | $ 578 | $ 1,740 |
Options | ||
Number | ||
Options granted (in shares) | 413,746 | |
Options exercised (in shares) | (30,192) | |
Options forfeited (in shares) | (169,008) | |
Options exercisable at the end of the period (in shares) | 1,272,727 | |
Average exercise price | ||
Options granted (in USD per share) | $ 2.01 | |
Options exercised (in USD per share) | 1.39 | |
Options forfeited (in USD per share) | 2.99 | |
Options exercisable at the end of the period (in USD per share) | $ 6.12 | |
Average remaining contractual life (in years) | ||
Options exercisable at the end of the period | 6 years 5 months 16 days | |
Aggregate intrinsic value (in thousands) | ||
Options exercisable at the end of the period | $ 64 | |
RSU | ||
Number | ||
RSUs granted (in shares) | 230,484 | |
RSUs vested (in shares) | (59,450) | |
RSUs forfeited (in shares) | (44,196) |
SHAREHOLDERS' EQUITY (Schedule of Options and RSUs Outstanding Which have been Separated into Ranges of Exercise Price) (Details) - $ / shares |
9 Months Ended | |
---|---|---|
Sep. 30, 2017 |
Dec. 31, 2016 |
|
Stock Options and RSUs | ||
Ranges of Exercise Price [Line Items] | ||
Options outstanding weighted average remaining contractual life (years) | 7 years 5 months 12 days | |
Options and RSU's outstanding (in shares) | 2,592,398 | 2,251,014 |
RSU | ||
Ranges of Exercise Price [Line Items] | ||
RSUs outstanding (in shares) | 353,437 | |
Options | ||
Ranges of Exercise Price [Line Items] | ||
Options exercisable (in shares) | 1,272,727 | |
Options exercisable weighted average remaining contractual life (years) | 6 years 5 months 16 days | |
Options | $0.82 | ||
Ranges of Exercise Price [Line Items] | ||
Range of exercise price, minimum (in USD per share) | $ 0.82 | |
Range of exercise price, maximum (in USD per share) | $ 0.82 | |
Options outstanding (in shares) | 31,803 | |
Options outstanding weighted average remaining contractual life (years) | 3 years 3 months 15 days | |
Options exercisable (in shares) | 31,803 | |
Options exercisable weighted average remaining contractual life (years) | 3 years 3 months 15 days | |
Options | $1.32 | ||
Ranges of Exercise Price [Line Items] | ||
Range of exercise price, minimum (in USD per share) | $ 1.32 | |
Range of exercise price, maximum (in USD per share) | $ 1.32 | |
Options outstanding (in shares) | 335,095 | |
Options outstanding weighted average remaining contractual life (years) | 4 years 9 months | |
Options exercisable (in shares) | 330,095 | |
Options exercisable weighted average remaining contractual life (years) | 4 years 8 months 1 day | |
Options | $1.47 - $2.20 | ||
Ranges of Exercise Price [Line Items] | ||
Range of exercise price, minimum (in USD per share) | $ 1.47 | |
Range of exercise price, maximum (in USD per share) | $ 2.20 | |
Options outstanding (in shares) | 762,937 | |
Options outstanding weighted average remaining contractual life (years) | 8 years 26 days | |
Options exercisable (in shares) | 338,830 | |
Options exercisable weighted average remaining contractual life (years) | 6 years 4 months 6 days | |
Options | $6.80- $8.99 | ||
Ranges of Exercise Price [Line Items] | ||
Range of exercise price, minimum (in USD per share) | $ 6.80 | |
Range of exercise price, maximum (in USD per share) | $ 8.99 | |
Options outstanding (in shares) | 663,382 | |
Options outstanding weighted average remaining contractual life (years) | 8 years 1 month 2 days | |
Options exercisable (in shares) | 322,536 | |
Options exercisable weighted average remaining contractual life (years) | 7 years 11 months 16 days | |
Options | $9.22- $10.98 | ||
Ranges of Exercise Price [Line Items] | ||
Range of exercise price, minimum (in USD per share) | $ 9.22 | |
Range of exercise price, maximum (in USD per share) | $ 10.98 | |
Options outstanding (in shares) | 201,343 | |
Options outstanding weighted average remaining contractual life (years) | 8 years 5 months 1 day | |
Options exercisable (in shares) | 75,586 | |
Options exercisable weighted average remaining contractual life (years) | 8 years 1 month 6 days | |
Options | $19.62-$20.97 | ||
Ranges of Exercise Price [Line Items] | ||
Range of exercise price, minimum (in USD per share) | $ 19.62 | |
Range of exercise price, maximum (in USD per share) | $ 20.97 | |
Options outstanding (in shares) | 244,401 | |
Options outstanding weighted average remaining contractual life (years) | 7 years 2 months 1 day | |
Options exercisable (in shares) | 173,877 | |
Options exercisable weighted average remaining contractual life (years) | 7 years 1 month 24 days |
SHAREHOLDER'S EQUITY (Share-based Awards to Non-Employee Consultants) (Details) - shares |
9 Months Ended | |
---|---|---|
Mar. 12, 2007 |
Sep. 30, 2017 |
|
RSU | ||
Share-based Goods and Nonemployee Services Transaction [Line Items] | ||
RSUs granted (in shares) | 230,484 | |
Non-employee Consultants | Nonemployee Options | ||
Share-based Goods and Nonemployee Services Transaction [Line Items] | ||
Options granted (in shares) | 3,454 | |
Non-employee Consultants | RSU | ||
Share-based Goods and Nonemployee Services Transaction [Line Items] | ||
RSUs granted (in shares) | 14,357 | |
Non-employee Consultants | Nonemployee Options and RSUs | ||
Share-based Goods and Nonemployee Services Transaction [Line Items] | ||
Options and RSUs outstanding (in shares) | 0 |
SHAREHOLDER'S EQUITY (Schedule of Warrants) (Details) - USD ($) |
9 Months Ended | |||
---|---|---|---|---|
Dec. 28, 2016 |
Dec. 30, 2015 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
Class of Warrant or Right [Line Items] | ||||
Proceeds from long term loan | $ 0 | $ 12,000,000 | ||
Term Loan | ||||
Class of Warrant or Right [Line Items] | ||||
Proceeds from long term loan | $ 20,000,000.0 | |||
Term Loan | 10.75% Term Loan Due January 2019 | ||||
Class of Warrant or Right [Line Items] | ||||
Proceeds from long term loan | $ 8,000,000 | |||
Warrants issued July 14, 2014 | ||||
Class of Warrant or Right [Line Items] | ||||
Warrants outstanding (in shares) | 403,804 | |||
Exercise price per warrant (in USD per share) | $ 10.08 | |||
Warrants exercisable (in shares) | 403,804 | |||
Warrants issued December 30, 2015 | ||||
Class of Warrant or Right [Line Items] | ||||
Warrants outstanding (in shares) | 119,295 | |||
Exercise price per warrant (in USD per share) | $ 9.64 | |||
Warrants exercisable (in shares) | 119,295 | |||
Minimum percentage of acquired company required to prevent warrants from becoming exercisable | 50.00% | |||
Warrants issued November 1, 2016 | ||||
Class of Warrant or Right [Line Items] | ||||
Warrants outstanding (in shares) | 2,437,500 | |||
Exercise price per warrant (in USD per share) | $ 4.75 | |||
Warrants exercisable (in shares) | 2,437,500 | |||
Warrants issued December 28, 2016 | ||||
Class of Warrant or Right [Line Items] | ||||
Warrants outstanding (in shares) | 47,717 | |||
Exercise price per warrant (in USD per share) | $ 9.64 | |||
Warrants exercisable (in shares) | 47,717 | |||
Number of warrants issued (in shares) | 47,717 | |||
Ordinary Share | ||||
Class of Warrant or Right [Line Items] | ||||
Warrants outstanding (in shares) | 3,008,316 | |||
Warrants exercisable (in shares) | 3,008,316 |
SHAREHOLDERS' EQUITY (Schedule of Non-cash Share-based Compensation Expense) (Details) - USD ($) $ in Thousands |
9 Months Ended | |
---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
|
Non-cash share-based compensation expense [Line Items] | ||
Non-cash share-based compensation expense | $ 2,597 | $ 2,458 |
Cost of revenues | ||
Non-cash share-based compensation expense [Line Items] | ||
Non-cash share-based compensation expense | 57 | 78 |
Research and development, net | ||
Non-cash share-based compensation expense [Line Items] | ||
Non-cash share-based compensation expense | 344 | 398 |
Sales and marketing, net | ||
Non-cash share-based compensation expense [Line Items] | ||
Non-cash share-based compensation expense | 585 | 606 |
General and administrative | ||
Non-cash share-based compensation expense [Line Items] | ||
Non-cash share-based compensation expense | $ 1,611 | $ 1,376 |
SHAREHOLDER'S EQUITY (Narrative- At-the-market offering program) (Details) - USD ($) |
9 Months Ended | 12 Months Ended | 17 Months Ended | |||||
---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 |
Dec. 31, 2016 |
Sep. 30, 2017 |
May 10, 2016 |
|||||
Share-based Goods and Nonemployee Services Transaction [Line Items] | ||||||||
Maximum amount which can be raised under ATM offering program | $ 25,000,000.0 | |||||||
Maximum amount which can be raised under shelf registration statement | $ 4,300,000.0 | $ 4,300,000.0 | ||||||
Stock issuance costs under equity distribution agreement as a percent of gross proceeds | 3.00% | |||||||
Issuance expenses | 389,000 | |||||||
ATM Offering Program | ||||||||
Share-based Goods and Nonemployee Services Transaction [Line Items] | ||||||||
Maximum amount which can be raised under ATM offering program | 25,000,000 | 25,000,000 | ||||||
Maximum amount which can be raised under shelf registration statement | 4,300,000.0 | 4,300,000.0 | ||||||
Issuance of ordinary shares in an ATM offering of ordinary shares, gross of issuance expenses | 9,400,000 | 14,000,000 | ||||||
Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses | 9,010,000 | [1] | $ 4,099,000 | 13,100,000 | ||||
Underwriter commission, fees and offering expenses | $ 439,000 | 907,000 | ||||||
Piper Jaffray | ATM Offering Program | ||||||||
Share-based Goods and Nonemployee Services Transaction [Line Items] | ||||||||
Issuance expenses | $ 420,000 | |||||||
Ordinary Share | ATM Offering Program | ||||||||
Share-based Goods and Nonemployee Services Transaction [Line Items] | ||||||||
Issuance of ordinary shares (in shares) | 5,379,908 | [1] | 692,062 | 6,071,970 | [1] | |||
Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses | $ 15,000 | [1] | $ 2,000 | |||||
Underwriter commission, fees and offering expenses | $ 439,000 | [1] | $ 468,000 | |||||
Maximum | ||||||||
Share-based Goods and Nonemployee Services Transaction [Line Items] | ||||||||
Stock issuance costs under equity distribution agreement as a percent of gross proceeds | 8.00% | |||||||
Weighted Average | ATM Offering Program | ||||||||
Share-based Goods and Nonemployee Services Transaction [Line Items] | ||||||||
Price per share of shares sold under ATM offering program (in USD per share) | $ 1.76 | $ 2.31 | ||||||
|
FINANCIAL EXPENSES, NET (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
Other Income and Expenses [Abstract] | ||||
Foreign currency transactions and other | $ (37) | $ 17 | $ (113) | $ 60 |
Financial expenses related to loan agreement with Kreos | 510 | 495 | 1,932 | 1,462 |
Bank commissions | 6 | 5 | 24 | 28 |
Income related to hedging transactions | 0 | (9) | 0 | (36) |
Financial expenses, net | $ 479 | $ 508 | $ 1,843 | $ 1,514 |
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Additional Information) (Details) |
9 Months Ended |
---|---|
Sep. 30, 2017
segment
| |
Segment Reporting [Abstract] | |
Number of reportable segments | 1 |
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Schedule of revenues within geographic areas) (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
Major customer data as a percentage of total revenues [Line items] | ||||
Revenues | $ 1,732 | $ 1,400 | $ 6,238 | $ 4,278 |
Israel | ||||
Major customer data as a percentage of total revenues [Line items] | ||||
Revenues | 0 | 0 | 0 | 0 |
United States | ||||
Major customer data as a percentage of total revenues [Line items] | ||||
Revenues | 801 | 710 | 4,242 | 2,976 |
Europe | ||||
Major customer data as a percentage of total revenues [Line items] | ||||
Revenues | 931 | 404 | 1,996 | 908 |
Asia-Pacific | ||||
Major customer data as a percentage of total revenues [Line items] | ||||
Revenues | $ 0 | $ 286 | $ 0 | $ 394 |
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Schedule long-lived assets by geographic region) (Details) - USD ($) $ in Thousands |
Sep. 30, 2017 |
Dec. 31, 2016 |
---|---|---|
Summary of revenues and long-lived assets by geographic region [Line items] | ||
Long-lived assets | $ 906 | $ 1,258 |
Israel | ||
Summary of revenues and long-lived assets by geographic region [Line items] | ||
Long-lived assets | 330 | 476 |
United States | ||
Summary of revenues and long-lived assets by geographic region [Line items] | ||
Long-lived assets | 361 | 565 |
Germany | ||
Summary of revenues and long-lived assets by geographic region [Line items] | ||
Long-lived assets | $ 215 | $ 217 |
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Schedule of major customer data as a percentage of total revenues) (Details) |
9 Months Ended | 12 Months Ended |
---|---|---|
Sep. 30, 2017 |
Dec. 31, 2016 |
|
Revenue | Customer concentration | Customer A | ||
Major customer data as a percentage of total revenues [Line items] | ||
Concentration risk (as a percent) | 42.60% | 33.30% |
SUBSEQUENT EVENTS (Details) |
9 Months Ended | ||||
---|---|---|---|---|---|
Oct. 05, 2017
shares
|
Oct. 04, 2017
option_holder
shares
|
Sep. 30, 2017
action
shares
|
Nov. 03, 2017
action
|
Nov. 01, 2017
action
|
|
Subsequent Event [Line Items] | |||||
Actions pending | action | 3 | ||||
Subsequent Event | |||||
Subsequent Event [Line Items] | |||||
Actions pending | action | 3 | 3 | |||
Options | |||||
Subsequent Event [Line Items] | |||||
Number of options tendered (in shares) | 169,008 | ||||
Award vesting period | 4 years | ||||
RSU | |||||
Subsequent Event [Line Items] | |||||
RSUs granted (in shares) | 230,484 | ||||
Exchange Program | Options | Subsequent Event | |||||
Subsequent Event [Line Items] | |||||
Number of option holders tendering options | option_holder | 46 | ||||
Number of options tendered (in shares) | 945,416 | ||||
Percentage of options tendered | 96.40% | ||||
Exchange Program | RSU | Subsequent Event | |||||
Subsequent Event [Line Items] | |||||
RSUs granted (in shares) | 251,872 | ||||
Award vesting period | 3 years | ||||
Exchange Program | RSU | Subsequent Event | Chief Executive Officer | |||||
Subsequent Event [Line Items] | |||||
RSUs granted (in shares) | 180,167 |
JXIF8K_ 1>0" ^98(S22!=74O;.&S6I8"J*OXV[T'$?QIMM.M'6
M">E$2&?";8S#QD Q\Z_<\R*S9B!V['W'PQ-O#BGVI@S.V(IXA\D[]%Z*S9?K
MC%V"T(0YCIATB9D1#-7G$.E:B&/Z'SU=IV]7,]Q&^G89?9^L"^Q6!7918/=/
MB?M/):YA;CX%88N>*K!-G"9'2M/K.,D+[SRP=_$1V0=\G/:?W#9".W(V'E\V
M]K\VQ@.FDESA"+7XP69#0NW#\0;/=ARST?"FFWX0F[]Q\1=02P,$% @
MPT-B2TA/C^CJ 0 9@4 !D !X;"]W;W)K 46:E>YBIL:>J\6,G7B>E?2Y :OXWY>+=O1YIA*<;8L
M.<,&60F'>9J-8R>/P?HA9-I-1CE:C:5NE_9;M'E6B^G[UQHAWV1V4"W<=$
M)7H-&^ 8-K1AKMD>YZZDP?QTL0^$[ +8"/:4[8*J*\WO[E&!K##"[EQ;U3R[
MUB;DL'EMWUP(>IT,!H1M$89+67$S>)^"HFD$$*1P925[$[PHO;1YL*9](_[D
M+8"J%JO?^XA!A"#P(K*G8(6<&Y_K3XX/:N\60.$I NZ 1U9U5Q5<@P5YTBWV
M]&K4NC^0F]]IQ0(AD_P[KWH_1#I0]^9\N]G$Q(2!F"VC; &D>9NRD1]A8J'
M%?:C794E6E]Y#^;8UTGNO< O>/REI<= AZ)[X-=*LHJ4$X8@>']WB"O8O$4,
M*;E+7\M17R=_.&):C8#AWIFC\2[:@WG9WMTBX^S2YFU]/SLAGA(5A'_Z9K
M\+T3?59X*WCX5VC'!S!1UV1XH%YCT[)D5B]H>U6.:N\0C (@, 1W^ Q>$.]PSNY9*M:0*>)4Z
MT[2G8<#L>9D/>K]-R@8SWX'%C&10XA<$,&AGZO/\:OG\(TIVP+D&@DK&JJ
M:_/J=!1\"FTL))HGVU2[73<<2*^3R[&XHSX##)*I+I6'"HF,2VR+%H;KZN*1
M=$NROM ))@Z8PU5UA,H^)%E@(#*VO'Y[J 5&EIJ46J XA:DGI>1[70>*S4RY
MLL]2 B6\ASG <#B#9CX(H[!Y-Y&<$PBA2120,*0
MQ6UJA7 4&(
0M[3SQ9^\
M@37E)],N"*=@ET;JUV:R.[8D:ZS?4&M_HUL5\[;^H>G[G*^$G\I&.'LFU0MM
MWM$C8Y(JE8&G8G96K=6XJ.A1ZNE"S7G?7_0+R=JA=_+'!B[_#5!+ P04
M" ##0V)++:KNI9\# !%$ &0 'AL+W=O
_P8<#^D3?[HFZ])]FIT5 /<#LI.Z'""6#V S,=YDVNG]'?-K40GKQ*2:.V8Z7!B3
M1"7I/BG+